Omar Dabbous
Tris Pharma (United States)(US)
Publications by Year
Research Areas
Neurogenetic and Muscular Disorders Research, RNA modifications and cancer, Acute Myocardial Infarction Research, Health Systems, Economic Evaluations, Quality of Life, Inflammatory Bowel Disease
Most-Cited Works
- → Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE)(2006)1,625 cited
- → A Validated Prediction Model for All Forms of Acute Coronary Syndrome(2004)1,579 cited
- → Determinants and Prognostic Impact of Heart Failure Complicating Acute Coronary Syndromes(2004)540 cited
- → Intervention in acute coronary syndromes: do patients undergo intervention on the basis of their risk characteristics? The Global Registry of Acute Coronary Events (GRACE)(2006)343 cited
- → Hyperuricemia in Young Adults and Risk of Insulin Resistance, Prediabetes, and Diabetes: A 15-Year Follow-up Study(2012)268 cited
- → Health outcomes in spinal muscular atrophy type 1 following AVXS‐101 gene replacement therapy(2018)214 cited
- → Impact of Chronic Constipation on Health-Related Quality of Life, Work Productivity, and Healthcare Resource Use: An Analysis of the National Health and Wellness Survey(2011)209 cited
- → Six-month outcomes in a multinational registry of patients hospitalized with an acute coronary syndrome (The Global Registry of Acute Coronary Events [GRACE])(2004)201 cited
- → Usefulness of microvolt T-wave alternans for prediction of ventricular tachyarrhythmic events in patients with dilated cardiomyopathy: results from a prospective observational study(2003)186 cited
- → Relationship of treatment delays and mortality in patients undergoing fibrinolysis and primary percutaneous coronary intervention. The Global Registry of Acute Coronary Events(2007)181 cited